Vi aspettiamo in tanti! Per ' #PIK3CA NEL CARCINOMA MAMMARIO METASTATICO HR+/HER2- VERSO UNA DIAGNOSI SEMPRE PIÙ PERSONALIZZATA!'
medicaecm.it/event/547/show…
Lavorare insieme per affrontare i temi che riguardano la Patologia Molecolare Predittiva e l'oncologia di precisione.

This narrative review summarizes the literature supporting the use of PARP inhibitors for breast cancer treatment, as well as potential future research directions. ja.ma/4ai7lDf

Post-neoadjuvant pembro in TNBC: yes or no? Lively debate at #EBCC14 by Ana Bosch MarleenKokLab Jean-Yves Pierga and Carmen Criscitiello

OncoAlert Europa Donna Michail ignatiadis FIORITA POULAKAKI Tanja Spanic Matteo Lambertini, MD PhD Elisabetta Bonzano Caroline Drukker EORTC Breast Cancer Group @breasteuropean

🙌Just out on @JAMAonc our review on PARPi for #breastcancer
Many steps have been made in the last 20 yrs; a vast amount is left waiting to be explored.
Great team effort led by Dana-Farber’s Breast Oncology Center and IEO.
Link 👉 jamanetwork.com/journals/jamao…

Just published ‼️our latest report on the ctDNA mutational analysis within the TREnd trial exploring palbociclib alone or in combo with ET in metatstatic breast cancer ascopubs.org/doi/full/10.12… Fondazione AIRC per la ricerca sul cancro G Curigliano MD PhD Carmen Criscitiello Cristina Guarducci LauraBiga Matteo Benelli

Suzette Delaloge, Erika Hamilton, MD, Evandro de Azambuja, MD, PhD, Carmen Criscitiello, FabriceAndre, Gustavo Werutski, Heather McArthur, MD, MPH, Peter Fasching & Nadia Harbeck highlight major reasons to submit your research to #ESMOBreast24 .
⏲️ Last 24 hrs to share your studies ⏲️
ow.ly/teFL50QzEhN
#BCSM

#ESMOBreast24 : Highlight your research on an international stage and contribute to the evolution of the #BreastCancer field. Submit your abstract by 13 February.
ow.ly/eP0W50QkW6E

#BCSM Erika Hamilton, MD Masakazu Toi Carmen Criscitiello MarleenKokLab Matteo Lambertini, MD PhD

Thanks for the brilliant thread, Simona Cristea!

Aside trials testing Innovations, there is a need for trials testing pragmatic questions in oncology. These trials must ↘️↘️ the nb of data collected & bureaucracy. This is 1 of the 4 pillars of clinical research strategy Gustave Roussy 1/2 thelancet.com/journals/lance…

#ESMOBreast24 : A platform to collaborate & discuss advances that could potentially shape the future of the #BreastCancer field. Share yr studies by 13 Feb.
ow.ly/SlA850QcPcR

Erika Hamilton, MD Carmen Criscitiello Matteo Lambertini, MD PhD Heather McArthur, MD, MPH Gustavo Werutsky MarleenKokLab Evandro de Azambuja, MD, PhD FabriceAndre

#ESMOBreast24 : Let your research findings stimulate discussions and help us drive progress in the #BreastCancer field. Submit your abstract by 13 February. 👉ow.ly/Wj2q50QaKCz
Erika Hamilton, MD judith balmaña Carmen Criscitiello Rebecca Dent Matteo Lambertini, MD PhD Heather McArthur, MD, MPH Otto Metzger…

A subset of ER+/HER2- #breastcancer may benefit from #immunotherapy , but which? Grade 3 alone (as in KN-756 & CM-7FL) is not such a precise selector.
Our study proposes a different & more precise way to identify these tumors.
📌 Read more: rdcu.be/dqys9

Giampaolo Bianchini

Check out our Dana-Farber’s Breast Oncology Center Editorial on Annals of Oncology: Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer? Erica Mayer Nancy Lin, MD Sara Tolaney #MBC #bcsm annalsofoncology.org/article/S0923-…

‘Influencer’ sì, ma della scienza! Sono ben 35 gli specialisti #IEO inseriti nel ranking aggiornato dei ricercatori più citati al mondo in ambito oncologico dalle riviste scientifiche internazionali relativamente alla produzione 2022.
Scopri di più👉🏼 lnkd.in/dEUK-JKf

A case-control study shows that breast tumors with estrogen receptor loss at metastatic relapse have intermediate features and clinical outcomes compared with metastatic luminal-like and ab initio triple-negative tumors
fondazionebonadonna.org/en/clinical-ou…
#fondazionebonadonna #oncology

Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study just published in #EuropeanJournalofCancer .
Stefania Morganti, MD Carmen Criscitiello
Read the full text here⬇️
ejcancer.com/article/S0959-…

There are only a few days left to apply for next year's PhD studentships at the CRUK Cambridge Institute! We are looking for a kind, collaborative and fun candidate to join our group. Apply here 👉
cruk.cam.ac.uk/job/phd-studen…

💥💥💥Thrilled to share the proof-edited final version of our pan-cancer analysis of #ADC targets and potential predictors of response 👉doi.org/10.1016/j.ejca…
Key points below 👇

#ESMO23 truly delivered on the ESMO promise to stand by the side of oncologists & make a difference in the lives of people with cancer. Many thanks to all of you who made this happen and see you in Barcelona for #ESMO24 .
ow.ly/u6IX50Q0U3p

silke gillessen Andres Cervantes

ReLive #ESMO2023
Domani 26 ottobre - Un webinar che racconta le novità emerse dal Congresso ESMO 2023.
Con C. Criscitiello Carmen Criscitiello, C. De Angelis Carmine De Angelis, M. Lambertini Matteo Lambertini, MD PhD.
Conduce la Prof.ssa Alessandra Fabi.
🎧Iscrizioni: overgroup.eu/evento/relive-…